OneThree’s Workflow for Biomarker and Indication Selection
OneThree’s Workflow for Biomarker and Indication Selection Background OneThree Biotech was born out of the largest precision medicine institute in America with the purpose of decreasing the failure rate of bringing therapeutics to market using biology driven artificial intelligence. Our technology was built in a lab setting; allowing us to engineer our methodologies around real-world […]
Brad Pryde Speaks at Charlton Morris on Using AI in Drug Discovery
Brad Pryde speaks at the Charlton Morris Using Artificial Discovery in Drug Discovery Webinar
Cory Gilvary Overviews how OneThree Biotech’s Gene Essentiality Module Can Help identify patients for Breast Cancer
Cory Gilvary Overviews how OneThree Biotech’s Gene Essentiality Module Can Help identify patients for Breast Cancer
Jubilant Therapeutics, OneThree Biotech ID Biomarkers for LSD1, HDAC6 Inhibitor
Jubilant Therapeutics, OneThree Biotech ID Biomarkers for LSD1, HDAC6 Inhibitor https://www.precisiononcologynews.com/cancer/jubilant-therapeutics-onethree-biotech-id-biomarkers-lsd1-hdac6-inhibitor#.Ya6LDC9abyV
OneThree selected as a finalist for two Reuters Entrepreneur Awards
OneThree selected as a finalist for two Reuters Entrepreneur Awards
Brad Pryde presents at BioDataWorld on digital transformation and ai in Drug Discovery
Brad Pryde presents at BioDataWorld on digital transformation and ai in Drug Discovery
Coryander Gilvary speaks at World Drug Safety Congress on Our AI Toxicity Prediction Platform
Coryander Gilvary speaks at World Drug Safety Congress on Our AI Toxicity Prediction Platform
OneThree Biotech Raises Seed Round For AI-Driven Drug Platform
OneThree Biotech Raises Seed Round For AI-Driven Drug Platform https://news.crunchbase.com/news/onethree-biotech-raises-seed-round-for-ai-driven-drug-platform/
Repositioning Approved Drugs as Combinations for MT Resistance
Repositioning Approved Drugs as Combinations for MT Resistance (This post relates to work done at Weill Cornell, where OneThree’s core technology was developed) This project is a bit of a followup from our previous collaboration with the Giannakakou lab where we identified and validated novel candidates that could act on cancer cells resistant to one […]
Predicting Genotype Specific Synergistic Combinations
Predicting Genotype Specific Synergistic Combinations (Before jumping in, I want to give a shout out to Coryandar Gilvary, a current graduate student at Weill Cornell. She led the work and was lead author on this method and is one of the best scientists working on machine learning for drug development I’ve met. This post relates […]